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Abstract
Background: MDM4 is a negative regulator of p53 and cooperates with MDM2 in the cellular
response to DNA damage. It is unknown, however, whether MDM4 gene alterations play some
role in the inherited component of breast cancer susceptibility.
Methods: We sequenced the whole MDM4 coding region and flanking untranslated regions in
genomic DNA samples obtained from 40 German patients with familial breast cancer. Selected
variants were subsequently screened by RFLP-based assays in an extended set of breast cancer
cases and controls.
Results: Our resequencing study uncovered two MDM4 coding variants in 4/40 patients. Three
patients carried a silent substitution at codon 74 that was linked with another rare variant in the
5'UTR. No association of this allele with breast cancer was found in a subsequent screening of 133
patients with bilateral breast cancer and 136 controls. The fourth patient was heterozygous for the
missense substitution D153G which is located in a less conserved region of the MDM4 protein but
may affect a predicted phosphorylation site. The D153G substitution only partially segregated with
breast cancer in the family and was not identified on additional 680 chromosomes screened.
Conclusion: This study did not reveal clearly pathogenic mutations although it uncovered two
new unclassified variants at a low frequency. We conclude that there is no evidence for a major
role of MDM4 coding variants in the inherited susceptibility towards breast cancer in German
patients.
Background
As part of a genome surveillance network, the tumour sup-
pressor protein p53 becomes stabilized after DNA damage
and modulates intracellular responses such as cell cycle
arrest, DNA repair, senescence or apoptosis [1-3]. Multi-
ple mechanisms regulate the activity of p53 at the post-
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transcriptional level [4,5]. One important antagonist,
MDM2, is essential for ubiquitylation and subsequent
degradation of p53 to maintain it at low levels in
unstressed cells [6]. An MDM2-related protein, MDM4,
has more recently emerged as another p53-interacting
protein with a central role in the DNA damage response
[7-9].
MDM4, also known as MDMX, is a 490 amino acid pro-
tein that is structurally related to MDM2 and binds to
both, p53 and MDM2 [8]. MDM4 is regarded a negative
regulator of p53 and cooperates with MDM2 to antago-
nize p53 [8-10]. In response to DNA double strand
breaks, MDM4 becomes phosphorylated by the ATM and
Chk2 kinases in an ATM-dependent manner which leads
to a switch from the degradation of p53 to the degrada-
tion of MDM4 and consecutive stabilization of p53 [9,11-
14].
Disruption of the p53 pathway is a key event in mammary
tumorigenesis, and MDM4 is overexpressed in some 19%
of breast carcinomas [15]. It is unknown, however,
whether the MDM4 gene plays some role in the inherited
component of breast cancer susceptibility. In the present
study, we investigated the mutational spectrum of the
whole  MDM4  coding sequence in a group of German
patients with familial breast cancer.
Methods
Patients
Our study population consists of a hospital-based series
of 1012 unselected breast cancer patients who were
treated at the Department of Radiation Oncology at Han-
nover Medical School from 1996–2001. Median age at
onset of breast cancer was 57 years in this patient group,
and 157 patients (15.8%) reported at least one first-degree
relative with breast cancer. The patient series had been
used previously to determine the frequency of selected
mutations in the BRCA1, ATM and CHEK2 genes [16-20]
as well as some more common polymorphisms in candi-
date genes tested by the Breast Cancer Association Con-
sortium [21-23]. Forty patients were selected for the
MDM4 resequencing study on the basis of (i) a family his-
tory of two or more first-degree relatives with breast can-
cer, or (ii) an age at onset of breast cancer below 50 years
plus a family history of one first degree relative with breast
cancer. Patients who were known carriers of a BRCA1 or
BRCA2 mutation were not included into this study. The
median age at onset for the 40 patients selected for the
sequencing study was 48 years. Population controls were
randomly taken from a consecutive series of anonymous
female German blood donors recruited in 2005 at the
same hospital. Written informed consent was obtained
from each patient, and the study was approved by the Eth-
ics commission at Hannover Medical School.
Mutation analyses
Genomic DNA was isolated from peripheral EDTA blood
samples using standard phenol-chloroform extraction. All
exons of the MDM4 gene were amplified by polymerase
chain reaction using primer pairs with sequences flanking
the respective exons (Table 1, Genbank NT_004487.18).
35 cycles of PCR were carried out using HotStart Taq DNA
Polymerase (Qiagen) with 1 min annealing at the primer
specific temperature (Table 1), 1 min extension at 72°C
and 1 min denaturation at 94°C. Sequencing reactions
were performed using BigDye v1.1 chemistry, and
sequences were evaluated on a Genetic Analyzer 3100
Avant (Applied Biosystems). Sequencing primers were the
same as the PCR primers (Table 1). The genomic region
covering exon 1 of the MDM4  gene was additionally
amplified in 133 breast cancer and 136 control samples to
allow for a subsequent restriction-enzyme based screen-
ing of the c.-103 T/C variant using MboI (New England
BioLabs). Reaction products were separated on a 2% aga-
rose gel and were evaluated by staining with GelRed. In
the presence of the c.-103T allele, PCR product was
cleaved to fragments of 129 bp and 282 bp, whereas prod-
uct from the C allele remained at 411 bp length. The
genomic region covering exon 7 of the MDM4 gene was
additionally amplified in 140 breast cancer and 200 con-
trol samples to allow for a subsequent restriction-enzyme
based screening of the D153G mutation using BbsI (New
England BioLabs). Reaction products were separated on a
3% agarose gel and were evaluated by staining with
GelRed. In the presence of the D153G mutation, the 334
bp wildtype product was cleaved to fragments of 110 and
224 bp, whereas the mutant product remained uncut. Pos-
itive and negative controls were included into each assay
and samples that remained uncut were subjected to direct
sequencing to avoid false positives.
Results
We established conditions to amplify the eleven exons of
the MDM4 gene (Table 1). The whole coding region and
flanking sequences were then analysed by direct sequenc-
ing in genomic DNA samples from 40 German breast can-
cer patients with a family history of disease. Eight distinct
sequence alterations were identified (Table 2). Six of these
were known polymorphisms listed in the NCBI SNP data-
base with four of them located in flanking intron
sequences, one in the 5'-UTR and one in the 3'-UTR. Max-
imum likelihood considerations indicated that the three
SNPs in the introns 8, 9 and 10 were in absolute linkage
disequilibrium, and that three common haplotypes could
be defined on the basis of either the rare allele of
rs4252697 in intron 5 (~16%), or the rare alleles of
rs4252717-rs2290855-rs2290854 in the intron 8-9-10
block (~26%), or the common alleles at these four loci
(~58%). Two less common alterations were identified in
the coding region, the silent V74V substitution in 3/40BMC Cancer 2008, 8:52 http://www.biomedcentral.com/1471-2407/8/52
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patients and the missense substitution D153G in a single
case (Table 2).
The V74V substitution is a synonymous transversion
c.222A>T that changes a GUA codon to GUU. It is located
within a weak potential alternative splice donor site, how-
ever maximum entropy calculations predicted that this
site is not improved by the substitution [24]. A search for
exonic splicing enhancer sequences predicted that the
substitution creates an additional binding site for the ser-
ine/arginine-rich (SR) protein SC35 which may improve
exon recognition [25]. However, preliminary analyses of
MDM4 mRNA in lymphoid cells did not reveal evidence
for alternative splicing of exon 4 (data not shown), and
this exon skipping is not among previously reported alter-
native splicing events [26,27]. On the basis of the availa-
ble information, we considered a functional contribution
of the V74V substitution unlikely and did not screen fur-
ther for this substitution. Of some interest, all three
patients who were heterozygous for V74V also carried the
variant c.-103C>T in the 5'-UTR (rs4252668), suggesting
that these two SNPs might be in linkage disequilibrium.
Table 1: Primers and PCR conditions used for MDM4 screening. Summary of primers, annealing temperatures and PCR product sizes 
for the eleven exons of the MDM4 gene. Forward and reverse primer sequences are listed. Exons 2 – 11 are coding exons. Exon 11 was 
amplified in two overlapping parts in order to make it more accessible to sequencing analysis.
Exon Primer Annealing (°C) Product size (bp)
1 5'-TCTGATCTCCTAATACACGTCTG-3'
5'-GCCTGCTCCTCACTCTCCAG-3'
62 416
2 5'-CTGGTTGCCTTTGTGTGAATG-3'
5'-CTGGGATTACAGTCATGAGAC-3'
62 296
3 5'-AGAGGTTCTCTTGTTCCATAG-3'
5'-GATCTGAGATCGCACCACTG-3'
62 253
4 5'-CAGATCAGTTCATTTCTGTGCTG-3'
5'-CATATTCTCAGTGCCTCATAGG-3'
62 520
5 5'-GATTCTGCCTTTGTATGCCTTAC-3'
5'-CTCAAAGCTGTGATACAGACTG-3'
62 234
6 5'-CAGCCAACATGGAGAAGTAC-3'
5'-CAGAGAAGGTTCACTCTGTC-3'
62 356
7 5'-GGTGAGCCAGAATGGAACTG-3'
5'-ACAATGGTAGTAACTAGGCTG-3'
62 334
8 5'-AGCTCTGCCACTAAGACAG-3'
5'-CAAGAGTAACCAAGAATGTTACC-3'
62 389
9 5'-GATGTAGTGTGACGACATTGAG-3'
5'-CAACAGATGATACTATGAGCAC-3'
62 311
10 5'-CTACTACTGAAATGCCAACTAGAAG-3'
5'-GGATTACATCATCTGAAGATGG-3'
62 329
11 (a) 5'-GCTTAGTGAGAGGATGTGAATG-3'
5'-CTGTCGTTAGACCTAAAGATGC-3'
59 431
11 (b) 5'-CTGTCGTTAGACCTAAAGATGC-3'
5'-CCTAAGAACATTCTCTGACAG-3'
59 475
Table 2: Genetic alterations of the MDM4 gene in 40 German patients with familial breast cancer. Survey of genetic alterations of the 
MDM4 gene identified in 40 patients with familial breast cancer. Mutations were designated according to the improved mutation 
nomenclature recommended by the Human Genome Variation Society [50]. Het, heterozygous; hom, homozygous. Variants c.-
103T>C and c.222A>T were identified in the same three individuals. The three SNPs c.672+28C>T, c.823-62T>C and c.903+20G>A 
were identified in the same 19 individuals, with 17 of them also carrying c.*+32A>C.
Location Nucleotide change Codon No. of carriers (frequency) NCBI database
het hom total
5'-UTR c.-103T>C none 3 (.08) - 3 (.08) rs4252668
Exon 4 c.222A>T Val74Val 3 (.08) - 3 (.08) not listed
Intron 5 c.343+9C>T none 12 (.30) 1 (.03) 13 (.33) rs4252697
Exon 7 c.458A>G Asp153Gly 1 (.03) - 1 (.03) not listed
Intron 8 c.672+28C>T none 19 (.48) - 19 (.48) rs4252717
Intron 9 c.823-62T>C none 19 (.48) - 19 (.48) rs2290855
Intron 10 c.903+20G>A none 19 (.48) - 19 (.48) rs2290854
3'-UTR c.*+32A>C none 17 (.43) - 17 (.43) rs4245739BMC Cancer 2008, 8:52 http://www.biomedcentral.com/1471-2407/8/52
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Because SNPs in the 5'-UTR can exert regulatory functions
in some genes with implications for breast cancer risk, e.g.
in RAD51 [28-31], we assessed the frequency of the rare
allele of rs4252668 in an additional set of 133 patients
with bilateral breast cancer and 136 population controls.
The rare allele was detected in 4/133 cases and 7/136 con-
trols suggesting that it does not confer a significant
increase in breast cancer risk (OR 0.6, 95% CI 0.2–2.0, p
= 0.38).
The second nucleotide change in the coding region gives
rise to a non-conservative amino acid substitution D153G
(Figure 1) and was identified in only one patient with
familial breast cancer. This patient had been diagnosed
with unilateral breast cancer by the age of 24 years. Her
mother had unilateral breast cancer by the age of 41 years
and basal cell carcinoma by the age of 49 years, and the
sister of the mother was diagnosed with unilateral breast
cancer by the age of 44 years. We confirmed the D153G
mutation in separate amplification reactions and also in
the patient's mother but not in the maternal aunt, indicat-
ing an incomplete segregation pattern. The D153G substi-
tution is embedded within a region of unknown structure
and with no apparent homology to MDM2. A screen for
evolutionary conservation with SIFT v.2.0 predicted this
substitution to be tolerated [32]. A search for exonic splic-
ing enhancers revealed that the D153G substitution is pre-
dicted to destroy a binding site for the SF2/ASF splicing
factor [25]. However, only one of two overlapping bind-
ing sites is affected by the substitution suggesting that
there might be no gross change in exon recognition. A
PROSITE search for protein binding and phosphorylation
sites revealed one possible motif, 150-TTED-153, which is
a predicted casein kinase II (CK2) phosphorylation site
[33]. We screened another 140 cases with bilateral breast
cancer and 200 random female control individuals for the
presence of the D153G mutation using a restriction
enzyme-based assay. No further carrier was detected indi-
cating that this missense substitution is very rare, at least
in the German population.
Discussion
Dysregulation of the p53 network is pivotal to mammary
carcinogenesis, and germline alterations in the TP53 and
MDM2 genes have been found to modulate the inherited
risk of breast cancer [34-39]. The MDM4 protein associ-
ates with and regulates both proteins, p53 and Mdm2, in
the DNA damage response pathway. It was therefore
tempting to investigate whether activating germ-line
mutations exist in the MDM4 coding sequence that could
also contribute to breast cancer risk. We thus sequenced
all exons and flanking non-coding sequences of MDM4 in
40 German patients with familial breast cancer. It is the
first study, to our knowledge, that assesses the frequency
distribution of MDM4 germ-line alterations in familial
breast cancer.
Outside of the coding region, we confirmed common sin-
gle nucleotide polymorphisms (SNPs) in the introns 5, 8,
9 and 10 as well as in the 5'- and 3' untranslated regions
(UTR). Although we cannot assign any function to these
SNPs, the SNPs in the untranslated regions may be useful
to measure allelic imbalances at the mRNA level. We also
noticed that there appeared to be a slight underrepresen-
tation of rare homozygotes for the coupled intronic vari-
ants in IVS8, 9 and 10 as one may have expected 2–3
Identification of the D153G mutation in exon 7 of the MDM4 gene Figure 1
Identification of the D153G mutation in exon 7 of the MDM4 gene. Identification of the D153G mutation in exon 7 of 
the MDM4 gene by direct sequencing. Left: control with wildtype sequence, right: heterozygosity for c.458A>G (D153G).BMC Cancer 2008, 8:52 http://www.biomedcentral.com/1471-2407/8/52
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homozygotes among the sequenced cases. This is not a
technical problem since we identified a homozygote
among a few additional samples after limited sequencing
of these portions of the gene. We think that it might be a
spurious observation due to a relatively small number of
fully sequenced samples but we cannot formally exclude
the possibility that there is selection. The data provided
here will enable subsequent studies that specifically
address the distribution of the three main haplotypes and
the corresponding genotypes in large case-control set-
tings. The NCBI SNP database also lists SNPs in the coding
region of MDM4, including two amino acid substitutions
(I175T, T406I) and two synonymous changes (E303E,
K468K) [40]. None of these are reported to surpass an
allele frequency of 0.05, and so it is not surprising that
none of them were found in our study. Instead, we identi-
fied two new single nucleotide variants in the coding
region, V74V and D153G.
The V74V substitution is a synonymous transversion, but
at least some synonymous changes can affect splicing,
mRNA stability or translational efficiency [41]. In silico
predictions for V74V did not provide strong support for a
role in splicing, and single exon skipping was not
observed as an alternative splicing event in MDM4 [26,27]
Another possibility would be that the silent substitution
acts at the translational level. Given that the GUA codon
has been classified as a "translationally weak" codon that
does not translate through wobble base-pairing, some
stimulating effect of its replacement by GUU on the
expression or on the folding properties of the MDM4 pro-
tein cannot finally be excluded [42-44]. However, both
codons are commonly used in the MDM4  coding
sequence and are represented seven and eight times,
respectively. Because all three patients who were hetero-
zygous for V74V also carried the variant c.-103C>T in the
5'-UTR (rs4252668), it remains possible that there is a
regulatory function associated with this allele. However,
the c.-103C>T variant is not predicted to target a transcrip-
tion factor binding site when tested by the TFSearch pro-
gram [45], and a screening of additional 269 individuals
did not reveal differences between the carrier frequencies
in cases and in controls. On the basis of all hitherto avail-
able information, we thus consider a functional or patho-
logical contribution of the c.-103C>T – V74V allele
unlikely.
The second nucleotide change in the coding region,
c.458A>G, gives rise to a non-conservative amino acid
substitution D153G and was identified in only one
patient with familial breast cancer. There was only partial
segregation of this substitution with breast cancer in the
single family but such observations have also been made
for other susceptibility alleles with low to moderate pene-
trance and do not exclude a possible contribution to
breast cancer risk. The D153G substitution is located
within a predicted casein kinase II (CK2) site. CK1 and
CK2 are two protein kinases that participate in a wide vari-
ety of cellular processes, including DNA repair and cell
cycle control, and phosphorylate Ser or Thr residues
flanked by Asp, Glu, or phosphorylated Ser residues in the
+3 or -3 position, respectively [46,47]. In some instances,
phosphorylation by CK1 or CK2 may be required to
license ATM substrate phosphorylation [48]. In MDM4,
Ser289 has been reported as a phosphorylation site for
CK1 while there is no report of MDM4 phosphorylation
by CK2 at Thr150 or other sites [49]. Furthermore, there
are multiple more CK2 sites predicted in the MDM4
sequence. Altogether, there is presently insufficient evi-
dence to conclude that the D153G variant exerts any effect
at the functional level. We did not find this substitution in
an additional set of 140 cases with bilateral breast cancer
and 200 random female control individuals indicating
that it is very rare, at least in the German population.
Therefore, its role for breast cancer, if any, might be very
limited and probably hard to be defined in future associ-
ation studies.
Altogether, this study did not support a major role for
MDM4 coding variants in familial breast cancer risk. It
remains possible that rare mutations exist which may
have been missed due to the relatively small sample size
of fully sequenced cases in our exploratory study. Further-
more, our families do not have extreme phenotypes and
therefore may be more likely to harbour polygenic suscep-
tibility alleles rather than highly penetrant mutations. It is
also possible that more families with the D153G muta-
tion may be detected in an extended case-control series.
However, several thousands of samples would have to be
screened to confirm, for instance, a 2–3 fold risk for a var-
iant with a carrier frequency of less than 1%. The paucity
of mutations in our study population seems to be consist-
ent with the lack of evidence from breast cancer linkage
studies for linkage to the MDM4 locus, and so highly pen-
etrant founder mutations in the MDM4 gene might at best
account for only a small proportion of German breast can-
cer patients.
Conclusion
In summary, a resequencing study of the MDM4 gene in
40 German breast cancer patients selected for family his-
tory did not reveal clearly pathogenic mutations although
it uncovered two new unclassified variants at a low fre-
quency. We conclude that there is no evidence for a major
role of MDM4 coding alterations in the inherited suscep-
tibility towards breast cancer in German patients.
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